Art and Science of Laboratory Medicine

Art and Science of Laboratory Medicine

Saturday, December 19, 2015

New test will replace PSA in prostate cancer screening in Sweden?

The prostate-specific antigen (PSA) test is used to screen for prostate cancer but has a high false-positive rate that translates into unnecessary prostate biopsies and overdiagnosis of low-risk prostate cancers. We aimed to develop and validate a model to identify high-risk prostate cancer (with a Gleason score of at least 7) with better test characteristics than that provided by PSA screening alone.

The Stockholm 3 (STHLM3) study is a prospective, population-based, paired, screen-positive, diagnostic study of men without prostate cancer aged 50–69 years randomly invited by date of birth from the Swedish Population Register kept by the Swedish Tax Agency.

The STHLM3 model could reduce unnecessary biopsies without compromising the ability to diagnose prostate cancer with a Gleason score of at least 7, and could be a step towards personalised risk-based prostate cancer diagnostic programmes.

Read more:
Prostate cancer screening in men aged 50–69 years (STHLM3): a prospective population-based diagnostic study

Source: The Lancet Oncology

No comments:

Follow "Art and Science of Laboratory Medicine " on: